Welcome to our dedicated page for Accuray Incorp SEC filings (Ticker: ARAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Accuray Incorporated (NASDAQ: ARAY) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures, including annual reports, quarterly reports and current reports on Form 8-K. As a radiation oncology company that develops and manufactures systems such as the CyberKnife and Radixact platforms, Accuray uses its SEC filings to report on financial performance, capital structure, governance decisions and material corporate events that matter to ARAY shareholders and analysts.
In its periodic reports, such as the Form 10-K and Form 10-Q, Accuray presents audited and unaudited financial statements, segment information, discussions of product and service revenue, gross profit, operating expenses, net income or loss, cash and debt balances, and non-GAAP measures like adjusted EBITDA. These filings also contain risk factor disclosures and management’s discussion and analysis, which address topics such as macroeconomic conditions, supply chain dynamics, tariffs, international operations and joint venture arrangements.
Current reports on Form 8-K provide more immediate insight into specific developments. Recent 8-K filings describe amendments to a financing agreement with TCW Asset Management Company LLC, including changes to liquidity calculations, delayed draw term loan conditions and covenant timing, as well as the issuance of warrants to purchase shares of common stock with defined exercise prices, terms and anti-dilution provisions. Other 8-Ks cover restructuring actions under a strategic, operational and organizational transformation plan, including workforce reductions and estimated restructuring charges, and governance matters such as equity incentive plan approvals, director elections, executive transitions and consulting arrangements.
Proxy materials, including the definitive proxy statement on Form DEF 14A, outline proposals submitted to stockholders, such as director elections, approval of the 2026 Equity Incentive Plan, advisory votes on executive compensation and ratification of the independent registered public accounting firm. These documents also describe corporate governance practices, board structure and executive compensation programs.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the significance of each filing. Real-time updates from the SEC’s EDGAR system ensure that new 10-K, 10-Q and 8-K reports, as well as proxy statements and other relevant forms, are available as they are filed. For those tracking insider-related information, Form 4 and other ownership filings can be reviewed alongside financial and governance disclosures to build a more complete picture of Accuray’s regulatory and corporate history.
The TCW Group, Inc., on behalf of the TCW Business Unit, reports beneficial ownership of 15,467,952 shares of Accuray Inc. common stock, representing about 11.5% of the class, including shares issuable upon exercise of warrants.
These warrants were issued on December 15, 2025 to TCW Rescue Financing and TCW Direct Lending in connection with amendments to a Financing Agreement. They include tranches with exercise prices of $1.25, $1.50, and $0.01 per share and expire on December 15, 2032. No separate consideration was paid for the December warrants, and none have been exercised. The stated purpose of issuing these warrants was to incentivize agreement to the financing amendments.
TCW Group Inc., a greater-than-10% owner of Accuray Inc. (ARAY), reported indirect holdings of multiple warrants to purchase common stock. These positions include warrants exercisable at $1.25 per share for 1,034,592 underlying shares and an additional 77,469 shares, and warrants at $1.50 for 1,448,429 and 108,457 underlying shares, each generally expiring in 2032. TCW-related entities also hold low-priced warrants at $0.01 and others at $1.68 per share with expirations in 2032, all reported as indirect ownership. A footnote explains that the warrants are held of record by TCW Rescue Financing Fund II LP and West Virginia Direct Lending LLC, and TCW disclaims beneficial ownership beyond any pecuniary interest.
Accuray Inc executive Paul Michael Miele, the company’s SVP and Chief Commercial Officer, submitted a Form 3, which is an initial statement of beneficial ownership of securities. This filing establishes his status as a reporting insider at Accuray but does not list any specific share transactions or holdings.
Accuray Incorporated amended its Consulting Agreement with Dedication Capital, LLC, an affiliate of director Steven F. Mayer. The amendment cuts by 50% the base consulting fee after March 31, 2026 through October 31, 2026 and reduces the minimum cash incentive amounts for the fiscal year ended June 30, 2026 and the fiscal quarter ended September 30, 2026. In exchange, time-based vesting was accelerated as of April 1, 2026 for 916,336 Initial Restricted Shares and all PSAs, while the remaining 333,004 Initial Restricted Shares vest on October 31, 2026. The changes are expected to generate at least $362,500 in cash savings for the company.
Accuray Incorporated has appointed Paul Miele as Senior Vice President and Chief Commercial Officer, effective April 6, 2026, as disclosed in a press release furnished under Regulation FD. He joins the executive leadership team to lead the company’s global commercial organization across sales, marketing, pricing, and market access.
The company highlights his prior success driving commercial turnarounds and double-digit annual sales growth in complex medical technology businesses. Accuray frames the hire as part of its ongoing transformation, aiming to strengthen commercial execution, grow systems and services sales, and enhance long-term value creation.
Accuray Inc SVP tax-withholding share disposition
Accuray Inc executive Sandeep Chalke, the SVP and Chief Commercial Officer, reported a tax-related share disposition. On this Form 4, 40,000 shares of Common Stock were withheld by the company at an implied price of $0.3881 per share to cover tax obligations tied to RSU vesting.
These shares were not sold in the open market but used to satisfy tax withholding and remittance requirements in a net settlement of restricted stock units. After this transaction, Chalke directly holds 419,806 shares of Accuray Inc common stock.
The Vanguard Group files an amendment (Schedule 13G/A) reporting 0 shares of Accuray Inc common stock. The amendment states Beneficial Ownership as 0 shares and 0% of the class as of 03/13/2026 and is signed on 03/26/2026.
The filing explains that on 01/12/2026 Vanguard completed an internal realignment and its subsidiaries or business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538; Vanguard states it no longer has beneficial ownership over securities held by those subsidiaries/divisions.
Accuray Incorporated entered into a separation agreement with Senior Vice President and Chief Commercial Officer Sandeep Chalke on March 13, 2026, ahead of his previously disclosed departure effective March 31, 2026. The agreement grants vesting of equity awards scheduled to vest on May 31, 2026, with all later equity forfeited. Mr. Chalke will receive a lump-sum cash payment of $459,000, equal to 12 months of base salary, plus a pro‑rated fiscal 2026 bonus paid on the same schedule as other executives. These benefits replace any prior severance or noncompetition payments, and the agreement, which includes a general release of claims, becomes effective after a seven‑business‑day revocation period.
Accuray SVP and COO Leonel Peralta reported equity compensation transactions involving restricted stock units and common stock. On February 28, 2026, he exercised 83,723 restricted stock units, receiving the same number of common shares at $0.00 per share. To satisfy tax withholding obligations related to this net settlement, 28,969 common shares were withheld by the company at $0.55 per share, as described in the footnote. After these transactions, Peralta directly owned 54,754 shares of Accuray common stock.